Efficacy of treatment outcomes of Intravitreal Antivascular Endothelial Growth factor injections and related risk factors in Diabetic macular edema
Dr. Virander Pal Singh, Dr. Suvidha Mahar, Dr. Natasha Makkar JCDR. 2018: 355-362
The primary goal of this study was to assess the efficacy of intensive aflibercept therapy in people with diabetic macular oedema (DME). The study additionally aimed to look into the modifiable systemic and ocular variables that affect therapy response in a practical scenario. Methodology: We conducted a retrospective analysis of the medical records of a cohort of patients diagnosed with diabetic macular oedema (DME). The evaluation of diabetic macular oedema (DME) involved the utilisation of central retinal thickness (CRT) and best-corrected visual acuity (BCVA). The study assessed the changes in contrast sensitivity and best-corrected visual acuity (BCVA) in response to each statistically significant factor. Results: The average central retinal thickness (CRT) and best-corrected visual acuity (BCVA) exhibited a significant improvement following the administration of five loading injections. Specifically, the CRT decreased to336.65 Â± 61.223 from 486.97 Â± 91.23 Î¼m, while the BCVA improved to0.39 Â± 0.21 LogMAR, with statistical significance (p < 0.05). Over the course of a 12-month follow-up period, it was seen that 16 eyes (53.33%) were able to sustain central retinal thickness (CRT) without requiring any supplementary treatment. Conclusion: In conclusion, administering five monthly loading doses of intravitreal aflibercept injection resulted in notable structural and optical enhancements among individuals diagnosed with diabetic macular oedema (DME).
This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access.
The articles in Journal of Cardiovascular Disease Research are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.
Copyright ï¿½ 2022 Journal of Cardiovascular Disease Research All Rights Reserved. Subject to change without notice from or liability to Journal of Cardiovascular Disease Research.
For best results, please use Internet Explorer or Google Chrome